Overly Quoted in BMCHelix About the Benefits of Automated IT Service Platforms
11 February 2020
Partner Mike Overly was quoted in the BMC Helix article, “A Single Point of Control: How IT Leaders Are Advocating for Automation Platforms.”
Overly noted that IT leaders believe a streamlined, automated service platform helps avoid the risks that disconnected solutions generate. Another way of saying it is “synergy,” said Overly.
“Instead of various individual systems operating or trying to operate together, you have an overarching automated solution bringing order to, all too frequently, chaos. As with anything, there are pros and cons. Overall, in my experience, automated platforms provide the synergistic value that justifies the risk.”
Overly noted that IT leaders believe a streamlined, automated service platform helps avoid the risks that disconnected solutions generate. Another way of saying it is “synergy,” said Overly.
“Instead of various individual systems operating or trying to operate together, you have an overarching automated solution bringing order to, all too frequently, chaos. As with anything, there are pros and cons. Overall, in my experience, automated platforms provide the synergistic value that justifies the risk.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”